Primary mesenchymal stem cells as a vaccine platform
AssigneeThe Administrators of the Tulane Educational Fund
InventorsSuzanne L. Tomchuck, Elizabeth B. Norton, Robert F. Garry, Bruce Bunnell, John D. Clements
Life of this patent
Estimating the term…
Abstract
Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.
Claims9
Episomally transfected primary mesenchymal stems cells (ETP-MSC) which episomally and transiently express at least one polypeptide having a sequence of a natural antigen from a pathogenic organism, or having a sequence that differs from the natural antigen by one or more conservative amino acid substitutions and sharing at least 50% sequence identity with the sequence of the natural antigen;
- and wherein the ETP-MSC elicit an antibody response to the antigen when the ETP-MSC are administered to a subject.
Dependencies are inferred from the claim text.